Bicara Therapeutics Inc.
BCAX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BCAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BCAX
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ficerafusp alfa (BCA101), a bifunctional antibody targeting EGFR and TGF-β, for the treatment of solid tumors. The company is currently conducting a Phase 2/3 trial in head and neck cancer and expects its existing cash to fund operations into the first half of 2029.
Key risk: Single product dependency
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.55B
Cash Runway
32.5 moLead Asset
ficerafusp alfa (Phase 2/Phase 3)Next Catalyst
Phase3_Topline · Jul 1, 2029Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 1 catalyst for Bicara Therapeutics Inc..
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ficerafusp alfa (BCA101), a bifunctional antibody targeting EGFR and TGF-β, for the treatment of solid tumors. The company is currently conducting a Phase 2/3 trial in head and neck cancer and expects its existing cash to fund operations into the first half of 2029.
- Lead product candidate is ficerafusp alfa (BCA101), a bifunctional antibody targeting EGFR and TGF-β, currently in a Phase 2/3 clinical trial for head and neck cancer [sec_mda · as of 2026-08-11].
- Cash and equivalents of $96.6M as of 2026-06-30, with a net loss of $55.4M for the quarter ended 2026-06-30 [sec].
- Accumulated deficit of $470.6M as of 2026-06-30 [sec_mda · as of 2026-08-11].
- Company expects existing cash to fund operations into the first half of 2029 [sec_mda · as of 2026-08-11].
- No revenue from product sales is expected unless and until regulatory approval is obtained, which is not anticipated for at least several years [sec_mda · as of 2026-08-11].
What works
- Ficerafusp alfa is a novel bifunctional antibody targeting both EGFR and TGF-β, which may offer a differentiated mechanism in solid tumors [sec_mda · as of 2026-08-11].
- The company has sufficient cash runway into the first half of 2029, providing a multi-year operational horizon without near-term financing pressure [sec_mda · as of 2026-08-11].
- A Phase 2/3 trial is ongoing, with a topline readout expected in 2029, representing a potential value inflection point [upcoming catalysts].
- The company has an ATM program in place for up to $150M in common stock sales, providing additional financing flexibility [sec_mda · as of 2025-11-10].
What to weigh
- The company has no approved products and no revenue from product sales; it is entirely dependent on the success of ficerafusp alfa [sec_mda · as of 2026-08-11].
- Accumulated deficit of $470.6M as of 2026-06-30 reflects substantial historical losses, and operating losses are expected to increase as clinical trials advance [sec_mda · as of 2026-08-11].
- The company will need to raise substantial additional capital to complete development and commercialization, and there is no guarantee of future funding [sec_mda · as of 2026-08-11].
- Clinical development is costly and uncertain; the timing and results of the Phase 2/3 trial are unpredictable and could be delayed or negative [sec_mda · as of 2026-08-11].
From the filings
Quoted directly from source documents.
Cash runway into first half of 2029
“Based upon our current operating plans, we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations and capital expenditure requirements into the first half of 2029.”
SEC MD&A · August 11, 2026
Accumulated deficit of $470.6M
“As of June 30, 2026, we had an accumulated deficit of $470.6 million.”
SEC MD&A · August 11, 2026
No product revenue expected for years
“We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for ficerafusp alfa or future product candidates, which will not be for at least the next several years, if ever.”
SEC MD&A · August 11, 2026
Catalyst timeline
- 2029-07-01 · Phase3_Topline · ficerafusp — Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C — Topline results from the Phase 2/3 trial of ficerafusp alfa in head and neck cancer are expected, which will be a key value inflection point for the company.
Risks & what to watch (4)›
Key risks
- Single product dependency — Company's future depends entirely on ficerafusp alfa; no other candidates in clinical development [sec_mda · as of 2026-08-11].
- Clinical trial uncertainty — Phase 2/3 trial may fail or be delayed; results are unpredictable and costly [sec_mda · as of 2026-08-11].
- Need for additional capital — Substantial additional funding required; no guarantee of availability on favorable terms [sec_mda · as of 2026-08-11].
- No revenue or approved products — No product sales revenue; operating losses expected to increase [sec_mda · as of 2026-08-11].
What to watch
- Phase 2/3 topline data for ficerafusp alfa expected around 2029-07-01 [upcoming catalysts].
- Cash burn rate and any updates to cash runway guidance in future SEC filings [sec_mda · as of 2026-08-11].
- Any use of the ATM program for additional financing [sec_mda · as of 2025-11-10].
- Regulatory updates or trial enrollment milestones for the ongoing Phase 2/3 study [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Bicara Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bicara Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
32.5 months
D/E 0.09 · 0% dilution
Lead: Phase 2/Phase 3
2 candidates
1 upcoming, next in ~1036d
0 buys · 39 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
144
Total value held
$1.06B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 7,255,993 | $144.3M |
| janus henderson group plc | 6,666,136 | $132.5M |
| deep track capital, lp | 4,062,500 | $80.8M |
| vanguard capital management llc | 3,548,440 | $70.6M |
| red tree management, llc | 3,170,509 | $63.1M |
| blackrock, inc. | 2,843,707 | $56.6M |
| omega fund management, llc | 2,392,150 | $47.6M |
| royalty pharma sub-manager, llc | 2,388,150 | $46.7M |
| fmr llc | 2,100,929 | $41.8M |
| citadel advisors llc | 1,726,242 | $34.3M |
Showing top 10 of 144 institutional holders of Bicara Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.0%
- Days to cover
- 15.7
- Shares short
- 8,896,472
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BCAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bicara Therapeutics Inc.?
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company developing ficerafusp alfa (BCA101), a bifunctional antibody targeting EGFR and TGF-β, for the treatment of solid tumors. The company is currently conducting a Phase 2/3 trial in head and neck cancer and expects its existing cash to fund operations into the first half of 2029.
What is Bicara Therapeutics Inc.'s lead drug candidate?
Bicara Therapeutics Inc.'s most advanced tracked candidate is ficerafusp alfa (Phase 2/Phase 3) for Metastatic Head and Neck Squamous Cell Carcinoma.
What is Bicara Therapeutics Inc.'s next catalyst?
Bicara Therapeutics Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C" — expected July 1, 2029.
Who is the CEO of Bicara Therapeutics Inc.?
Dr. Claire Mazumdar Clemon M.B.A., Ph.D. is the chief executive officer of Bicara Therapeutics Inc. (BCAX).
Where is Bicara Therapeutics Inc. headquartered?
Bicara Therapeutics Inc. (BCAX) is headquartered in Boston, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.